KVUE Share Price Performance
US$17.33
-4.74 (-21.48%)
10.4% undervalued intrinsic discount
US$19.33
Fair Value
Price US$17.33
AnalystConsensusTarget US$19.33
julio US$25.09
Fair ValueUS$19.33
Share Pricen/a
Kenvue Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 99 Fair Values set on narratives written by author
KVUE Community Narratives
AN
Fair Value US$19.33 10.4% undervalued intrinsic discount
Analyst Commentary Highlights Legal Risks and Valuation Adjustments for Kenvue Amid Market Uncertainty
0users have liked this narrative
0users have commented on this narrative
47users have followed this narrative
JU
Fair Value US$25.09 30.9% undervalued intrinsic discount
J&J spinoff
1users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
J&J spinoff
Bulls With autonomy from its former parent, Kenvue can allocate resources to best fit its needs and grow the business. Macro drivers like an aging population and premiumization of health care will act as tailwinds for all of Kenvue ’ s brands.Read more
1users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
JU
US$25.09
30.9% undervalued intrinsic discount
julio's Fair Value
Revenue
8.7% p.a.
Profit Margin
13.3%
Future PE
24x
Price in 2034
US$59.35
Analyst Commentary Highlights Legal Risks and Valuation Adjustments for Kenvue Amid Market Uncertainty
Key Takeaways Enhanced digital capabilities and operational streamlining are expected to boost market share, cost efficiency, and margins while supporting continued revenue growth. Focus on innovation and emerging markets positions the company for sustained demand, premium pricing, and long-term expansion beyond mature regions.Read more
0users have liked this narrative
0users have commented on this narrative
47users have followed this narrative
AN
US$19.33
10.4% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
2.79% p.a.
Profit Margin
12.94%
Future PE
22.3x
Price in 2028
US$24.36
Trending Discussion
Recently Updated Narratives
JU
J&J spinoff
Fair Value: US$25.09 30.9% undervalued intrinsic discount
7 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
KVUE: Share Price Will Recover As Legal Overhangs Ease Under Kimberly-Clark Deal
Fair Value: US$19.33 10.4% undervalued intrinsic discount
47 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Kenvue Inc. Key Details
About KVUE
- Founded
- 2022
- Employees
- 22000
- CEO
- WebsiteView website
Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women’s health, wound, and other care products under the Listerine, Johnson’s, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
